Myriad advances cancer diagnostic
This article was originally published in The Gray Sheet
Executive SummaryMyriad Genetics introduces the BRACAnalysis Rearrangement DNA sequencing assay Aug. 1 for prediction of breast and ovarian cancer in high-risk women. The molecular test, which is the first commercially available to detect rare "large rearrangement" genetic mutations, will be used as an adjunct for "exceptionally" high-risk women who test negative with Myriad's already available BRACAnalysis test. A study published in the Journal of the American Medical Association in March signaled the need for such a test to help identify cancer-predisposing genes in up to 12% of high-risk women testing negative with Myriad's broader assay (1"The Gray Sheet" March 27, 2006, p. 15)...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.